A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Medivation
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 14 Jun 2017 This trial has been completed in Spain
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top